Jesus Esquivel1. 1. Department of Surgical Oncology, Cancer Treatment Centers of America, Philadelphia, PA 19124, USA.
Abstract
BACKGROUND: Chemotherapy hyperthermic intraperitoneal chemotherapy (HIPEC) is playing an ever increasing role in the management of colorectal cancer (CRC) with peritoneal metastases (PM) as results approach those of surgical resection of liver metastases. Selection criteria for treatment type, sequence and timing of currently available therapies remain ill-defined. METHODS: We review the current published literature analyzing outcomes by treatments with surgery, systemic chemotherapy, cytoreductive surgery (CRS) and HIPEC, and ongoing clinical trials. A clinical pathway that incorporates all currently available therapies, determining the timing and sequence of such therapies was constructed. RESULTS: Most of the literature on outcome data comes from studies reporting the results of CRS and HIPEC with large series showing a median survival of 32-47 months. Meanwhile, the vast majority of patients, over 90% in the United States, are being treated with palliative systemic therapies following the NCCN guidelines. CONCLUSIONS: Cooperation between medical and surgical oncologists represents an unmet need in oncology when it comes to patients with CRC with PM. The presented clinical pathway constitutes a feasible and much needed first step to start this cooperation.
BACKGROUND: Chemotherapy hyperthermic intraperitoneal chemotherapy (HIPEC) is playing an ever increasing role in the management of colorectal cancer (CRC) with peritoneal metastases (PM) as results approach those of surgical resection of liver metastases. Selection criteria for treatment type, sequence and timing of currently available therapies remain ill-defined. METHODS: We review the current published literature analyzing outcomes by treatments with surgery, systemic chemotherapy, cytoreductive surgery (CRS) and HIPEC, and ongoing clinical trials. A clinical pathway that incorporates all currently available therapies, determining the timing and sequence of such therapies was constructed. RESULTS: Most of the literature on outcome data comes from studies reporting the results of CRS and HIPEC with large series showing a median survival of 32-47 months. Meanwhile, the vast majority of patients, over 90% in the United States, are being treated with palliative systemic therapies following the NCCN guidelines. CONCLUSIONS: Cooperation between medical and surgical oncologists represents an unmet need in oncology when it comes to patients with CRC with PM. The presented clinical pathway constitutes a feasible and much needed first step to start this cooperation.
Entities:
Keywords:
Cytoreductive surgery (CRS); colorectal cancer (CRC); hyperthermic intraperitoneal chemotherapy (HIPEC); peritoneal carcinomatosis
Authors: Jan Franko; Qian Shi; Charles D Goldman; Barbara A Pockaj; Garth D Nelson; Richard M Goldberg; Henry C Pitot; Axel Grothey; Steven R Alberts; Daniel J Sargent Journal: J Clin Oncol Date: 2011-12-12 Impact factor: 44.544
Authors: Jesus Esquivel; Andrew M Lowy; Maurie Markman; Terence Chua; Joerg Pelz; Dario Baratti; Joel M Baumgartner; Richard Berri; Pedro Bretcha-Boix; Marcello Deraco; Guillermo Flores-Ayala; Olivier Glehen; Alberto Gomez-Portilla; Santiago González-Moreno; Martin Goodman; Evgenia Halkia; Shigeki Kusamura; Mecker Moller; Guillaume Passot; Marc Pocard; George Salti; Armando Sardi; Maheswari Senthil; John Spilioitis; Juan Torres-Melero; Kiran Turaga; Richard Trout Journal: Ann Surg Oncol Date: 2014-05-23 Impact factor: 5.344
Authors: D Elias; D Goéré; F Dumont; C Honoré; P Dartigues; A Stoclin; D Malka; V Boige; M Ducreux Journal: Eur J Cancer Date: 2013-10-21 Impact factor: 9.162
Authors: Jan Franko; Zuhaib Ibrahim; Niraj J Gusani; Matthew P Holtzman; David L Bartlett; Herbert J Zeh Journal: Cancer Date: 2010-08-15 Impact factor: 6.860
Authors: O Glehen; F Kwiatkowski; P H Sugarbaker; D Elias; E A Levine; M De Simone; R Barone; Y Yonemura; F Cavaliere; F Quenet; M Gutman; A A K Tentes; G Lorimier; J L Bernard; J M Bereder; J Porcheron; A Gomez-Portilla; P Shen; M Deraco; P Rat Journal: J Clin Oncol Date: 2004-08-15 Impact factor: 44.544
Authors: Tanja Grimmig; Eva-Maria Moll; Kerstin Kloos; Rebecca Thumm; Romana Moench; Simone Callies; Jennifer Kreckel; Malte Vetterlein; Joerg Pelz; Buelent Polat; Sudipta Tripathi; Roberta Rehder; Carmen M Ribas; Anil Chandraker; Christoph-T Germer; Ana Maria Waaga-Gasser; Martin Gasser Journal: Cancer Growth Metastasis Date: 2017-09-18
Authors: Nina R Sluiter; Koen P Rovers; Youssra Salhi; Stijn L Vlek; Veerle M H Coupé; Henk M W Verheul; Geert Kazemier; Ignace H J T de Hingh; Jurriaan B Tuynman Journal: Ann Surg Oncol Date: 2018-05-31 Impact factor: 5.344
Authors: F M K Elekonawo; W J van Eden; W Y van der Plas; R S G Ewalds; L A W de Jong; A J A Bremers; P H J Hemmer; N F M Kok; S Kruijff; A G J Aalbers; P R de Reuver Journal: BJS Open Date: 2020-01-16